Advanced search

Filters

Country

All countries

North America

South America

Europe

Africa

Middle East

Asia

Oceania

Central America

Select all

Capitalization

Sector

All sectors

  Energy

  Basic Materials

  Industrials

  Consumer Cyclicals

  Consumer Non-Cyclicals

  Financials

  Healthcare

  Technology

  Utilities

  Real Estate

  Institutions, Associations & Organizations

  Government Activity

  Academic & Educational Services

Select all

Add a keyword

Announcement Date

Since

Until

107 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Regulus Therapeutics Inc. announced that it has received $100.000267 million in funding from a group of investors
CI
Biogen : Announces 2023 Annual Shareholder Meeting Preliminary Results
PU
Regulus Therapeutics Announces Appointment of Preston S. Klassen, M.D. to its Board of Directors
PR
Sarissa's Denner quits Biogen board as firm seeks seats at Alkermes
RE
Biogen Announces Changes to Its Board of Directors
GL
Biogen Announces Changes to Its Board of Directors
AQ
Biogen Announces Changes to Its Board of Directors
CI
Declaration of Voting Results by Exelixis Inc
CI
Exelixis Files Definitive Proxy Statement and Mails Letter to Shareholders
BU
Exelixis Solicits Proxies from Shareholders
CI
Exelixis Advances Board Refreshment Plan
BU
REGULUS THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
BIOGEN INC. : Change in Directors or Principal Officers, Other Events (form 8-K)
AQ
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
GL
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of Directors
AQ
Biogen Inc. Announces Board Changes
CI
Regulus Therapeutics Announces Resignation of Board Member
PR
JPMorgan to expand in Greece with new office, payments team
RE
J.P. Morgan to Expand in Greece
BU
Biogen Names Christopher Viehbacher President and Chief Executive Officer
GL
Biogen Names Christopher Viehbacher President and Chief Executive Officer
AQ
Biogen : Names Christopher Viehbacher President and Chief Executive Officer - Form 8-K
PU
BIOGEN INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
REGULUS THERAPEUTICS INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
EXELIXIS, INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Exelixis Announces Charles Cohen, Ph.D., to Retire from Board of Directors
BU
20 years of COSMOTE Scholarships: 30 new students joined COSMOTE’s family of 750 scholars
PU
Biogen : Announces Nancy Leaming and Brian Posner to Retire from Board of Directors - Form 8-K
PU
Biogen Announces Nancy Leaming and Brian Posner to Retire from Board of Directors
AQ
Exelixis Elects Jacqueline Wright to Its Board of Directors
AQ
Exelixis Elects Jacqueline Wright to Its Board of Directors
BU
Regulus Therapeutics : SECURITIES PURCHASE AGREEMENT - Form 8-K
PU
REGULUS THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)
AQ
Regulus Therapeutics Inc. announced that it expects to receive $34.624999 million in funding from New Enterprise Associates, Inc., Federated Hermes, Inc.
CI
Biogen : Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development - Form 8-K
PU
Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development
GL
Biogen Announces Alfred W. Sandrock, Jr. to Retire as Head of Research & Development
GL
REGULUS THERAPEUTICS INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Transcript : Exelixis, Inc. Presents at Goldman Sachs 42nd Annual Global Healthcare Conference, Jun-09-2021 01:20 PM
BIOGEN INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Transcript : Biogen Inc. - Shareholder/Analyst Call
EXELIXIS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
Transcript : Exelixis, Inc. - Shareholder/Analyst Call
Biogen Announces Two New Nominees for Election to Board of Directors
GL
REGULUS THERAPEUTICS INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
AQ
Regulus Therapeutics Inc. announced that it has received $19.383037 million in funding from a group of investors
CI
REGULUS THERAPEUTICS INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
BIOGEN INC. : Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits (form 8-K)
AQ
Transcript : Biogen Inc. - Shareholder/Analyst Call
EXELIXIS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
No results for this search
  1. Stock Market
  2. Advanced search
  3. Stelios Papadopoulos
  4. News